EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world evidence to support health technology assessment and payer decision making: is it now or never?

Linda A Murphy iD, Ron Akehurst, David Cunningham, Gérard de Pouvourville, Oriol Solà-Morales iD

International Journal of Technology Assessment in Health Care · 2025

DOI: 10.1017/s0266462325000145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Technology Assessment in Health Care, 2025. Verfasst von Linda A Murphy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lumanity Inc, Sheffield, UK. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Decision Making. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The aim of this policy article is twofold: (i) to provide a summary and update of recent important policy developments, in particular relevant guidance on the use of real-world data/real-world evidence (RWD/RWE) by health technology assessment (HTA) bodies and (ii) to set out our policy recommendations on how the different elements of an “RWE framework” we have previously developed could support, further enhance and facilitate the use of RWE for HTA purposes and by HTA bodies and payers.

Methods

We undertook a targeted review and analysis of recent important policy developments. The aim was to build on our recommendations from previous work on the “RWE Framework,” and consider how the relevant tools from our Framework can further enhance and facilitate the use of RWE for HTA purposes and by HTA bodies/payers.

Results

We provide eight conditions that we argue would, in combination, constitute the optimal use and acceptance of RWD/RWE for HTA. We believe that, should the eight conditions hold, RWD/RWE would enable more efficient access to medicines and healthcare technologies for patients.

Conclusions

High-quality, fit-for-purpose RWD/RWE can and should be used more frequently in HTA. Multi-stakeholder and cross-geography collaborative partnerships are needed to align on best practices to optimize the evidence that needs to be generated to satisfy all stakeholders’ needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalDecision MakingHumansHealth PolicyPolicy Making

Stichwörter der Autor:innen

clinical needdata governanceguidancehealth technology assessmentpayerspopulation healthreal-world datareal-world evidence

Autor:innen und Institutionen

  • Lumanity Inc, Sheffield, UK.
  • Independent Consultant, Surrey, UK.
  • ESSEC Business School, Cergy, France.
  • Fundació HiTT, Barcelona, Spain.

ORCID-Profile: Linda A Murphy, Oriol Solà-Morales

Förderung

  • Novartis

Zitieren

APA

Murphy, L. A., Akehurst, R., Cunningham, D., de Pouvourville, G., & Solà-Morales, O. (2025). Real-world evidence to support health technology assessment and payer decision making: is it now or never?. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/s0266462325000145

Vancouver

Murphy LA, Akehurst R, Cunningham D, de Pouvourville G, Solà-Morales O. Real-world evidence to support health technology assessment and payer decision making: is it now or never?. International Journal of Technology Assessment in Health Care. 2025. doi:10.1017/s0266462325000145

BibTeX
@article{Murphy2025,
  author = {Murphy, Linda A and Akehurst, Ron and Cunningham, David and de Pouvourville, Gérard and Solà-Morales, Oriol},
  title = {Real-world evidence to support health technology assessment and payer decision making: is it now or never?},
  journal = {International Journal of Technology Assessment in Health Care},
  year = {2025},
  doi = {10.1017/s0266462325000145}
}
Kostenlos starten →